Showing results (81-90 of 120) with videos related to
Sort By:
Pageof 12
Pharmacoeconomics - Open|February 20, 2025
Cost Effectiveness of Left Ventricular Assist Devices (LVADs) as Destination Therapy: A Systematic ReviewTuba Saygın Avşar, Louise Jackson, Pelham Barton, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2005
Up-regulation of EphB4 in mesothelioma and its biological significanceGuangbin Xia, S Ram Kumar, Rizwan Masood, et al.Urologic Oncology|November 13, 2012
Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern CaliforniaAdrian S Fairey, Siamak Daneshmand, David Quinn, et al.Cancer Letters|July 14, 2018
Suppression of ribosomal protein RPS6KB1 by Nexrutine increases sensitivity of prostate tumors to radiationSuleman S Hussain, Shih-Bo Huang, Roble G Bedolla, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2011
Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 studyTanya B Dorff, Thomas W Flaig, Catherine M Tangen, et al.Urologic Oncology|May 11, 2010
Tumor cytoreduction results in better response to androgen ablation--a preliminary report of palliative transurethral resection of the prostate in metastatic hormone sensitive prostate cancerXiao-Jian Qin, Chun-Guang Ma, Ding-Wei Ye, et al.Molecular Oncology|October 7, 2015
p53-based strategy to reduce hematological toxicity of chemotherapy: A proof of principle studyChul S Ha, Joel E Michalek, Richard Elledge, et al.Health Technology Assessment (Winchester, England)|August 27, 2024
Clinical and cost-effectiveness of left ventricular assist devices as destination therapy for advanced heart failure: systematic review and economic evaluationSophie Beese, Tuba S Avşar, Malcolm Price, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2018
Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921Maha Hussain, Catherine M Tangen, Ian M Thompson, et al.Clinical Genitourinary Cancer|March 9, 2020
Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent StudiesAlessandro Tafuri, David D Smith, Giovanni E Cacciamani, et al.Pageof 12